Abstract: Slide Presentations |

The Effectiveness of Fluticasone Propionate/Salmeterol 100/50mcg Diskus® (FSC) as an Inhaled Corticosteroid-Sparing Agent: Effect of Baseline Asthma Severity FREE TO VIEW

Paul M. Dorinsky, MD; Steve W. Yancey, MS; Donna Reilly, BS; Lisa Edwards, PhD
Author and Funding Information

GlaxoSmithKline, Research Triangle Park, NC


Chest. 2003;124(4_MeetingAbstracts):87S-b-88S. doi:10.1378/chest.124.4_MeetingAbstracts.87S-b
Text Size: A A A
Published online


PURPOSE:  Recently, FSC was shown to permit a 60% reduction in the ICS dose while maintaining asthma control in patients requiring fluticasone propionate (FP) 250mcg BID for asthma stability. The purpose of this post-hoc analysis was to assess the impact of baseline asthma severity on the ICS-sparing properties of FSC.

METHODS:  Lung function, albuterol use and asthma symptom data from two, replicate, double-blind, 12-week, parallel group studies were evaluated for patients with baseline FEV1 ≥80% vs. <80% predicted at randomization.

RESULTS:  Data below represents change from baseline (SE) at the 12-week endpoint.

CONCLUSION:  FSC was an effective ICS-sparing agent regardless of baseline asthma severity, allowing the ICS dose to be reduced by 60% while improving overall asthma control.

CLINICAL IMPLICATIONS:  Treating the two main components of asthma (inflammation and smooth muscle dysfunction) with a low dose ICS and a long-acting β2-agonist is a more effective treatment strategy than a higher dose ICS alone. ParameterFEV1 ≥80% PredictedFEV1 <80% PredictedFSC n=284FP 250 n=273FSC n=288FP 250 n=279# Pts withdrawn*33473138Baseline FEV1 % predicted88.5 (0.41)88.1 (0.36)72.7 (0.27)72.8 (0.26)FEV1 (L) Baselline2.98 (0.04)2.98 (0.04)2.47 (0.03)2.48 (0.04) Change0.04 (0.01)−0.05 (0.02)0.09 (0.01)−0.01 (0.02)AM PEF (L/min) Baseline472.3 (8.2)468.9 (9.0)438.5 (7.5)421.4 (8.3) Change35.3 (3.9)18.7 (4.1)39.4 (3.9)19.8 (3.3)Albuterol use (puffs/24 hrs) Baseline0.75 (0.07)0.87 (0.08)0.97 (0.07)1.04 (0.08) Change−0.25 (0.06)−0.20 (0.07)−0.36 (0.08)−0.20 (0.07)% Symptom Free days Baseline46.2 (2.5)43.5 (2.6)38.4 (2.5)38.9 (2.3) Change11.7 (1.8)4.8 (1.8)11.0 (2.0)5.9 (1.8)*

due to worsening asthma;

p≤0.02 FSC vs. FP 250

DISCLOSURE:  P.M. Dorinsky, Employee of GSK, Industry.

Monday, October 27, 2003

2:30 PM - 4:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
Management of asthma.
Singapore Ministry of Health | 7/18/2008
Adapting your practice: treatment and recommendations for homeless patients with asthma.
National Health Care for the Homeless Council, Inc. | 6/13/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543